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Abstract: Primary varicella-zoster virus (VZV) infection causes varicella (chickenpox) and the
establishment of a lifelong latent infection in ganglionic neurons. VZV reactivates in about one-third
of infected individuals to cause herpes zoster, often accompanied by neurological complications.
The restricted host range of VZV and, until recently, a lack of suitable in vitro models have seriously
hampered molecular studies of VZV latency. Nevertheless, recent technological advances facilitated
a series of exciting studies that resulted in the discovery of a VZV latency-associated transcript (VLT)
and provide novel insights into our understanding of VZV latency and factors that may initiate
reactivation. Deducing the function(s) of VLT and the molecular mechanisms involved should now
be considered a priority to improve our understanding of factors that govern VZV latency and
reactivation. In this review, we summarize the implications of recent discoveries in the VZV latency
field from both a virus and host perspective and provide a roadmap for future studies.
Keywords: varicella-zoster virus; latency; reactivation; sensory ganglia; VZV latency-associated
transcript; open reading frame 63; RNA-sequencing; epigenetics; immunity
1. Introduction
Most adults worldwide are infected with the neurotropic human alphaherpesvirus,
varicella-zoster virus (VZV) [1]. VZV is the causative agent of two distinct diseases: a generalized
vesicular skin rash referred to as varicella (chickenpox), and a localized dermatomal skin rash referred
to as herpes zoster (HZ; shingles) [2]. Although varicella and HZ were known to be related [3],
it was not until 1965 that the British general practitioner, Dr Robert E. Hope-Simpson, suggested that
“herpes zoster is a spontaneous manifestation of varicella infection”. This observation was based on a careful
examination of ~3500 patients, including 192 HZ cases, who visited his practice over a 16-year period,
combined with cautious reading of the available anatomical and epidemiological literature regarding
HZ. This led to his famous hypothesis that: “Following the primary infection (chickenpox), virus becomes
latent in the sensory ganglia, where it can be reactivated from time to time (herpes zoster)” [4]. Eighteen
years later, this hypothesis was proven by Dr Donald Gilden’s crucial discovery of VZV DNA in
latently infected human ganglia [5]. Although we have learned much about VZV biology in general in
previous decades, the mechanisms underlying VZV latency and reactivation have remained enigmatic,
at least in part due to VZV being a human tropic pathogen that does not cause disease in experimental
animal models. However, recent insights into the VZV latency program and newly developed in vitro
models using human embryonic stem cell (hESC)-derived neurons for studying viral latency and
reactivation have now set the stage to unravel the molecular mechanisms that regulate VZV latency.
In preparing this review, we sought to be inclusive of as many view points as possible but to consider
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only human-derived cell- or tissue-based systems (animal models utilised for VZV studies are the
subject of another review in this issue). At the outset, we therefore limit this review to only include
studies of VZV latency in which there is a demonstrable lack of infectious virus production and/or
any observable pathology.
2. Molecular Biology of VZV
2.1. Structure and Genomic Organization of VZV
VZV particles are pleomorphic to spherical in shape, ~150–200 nm in diameter and are composed
of three proteinous layers: a nucleocapsid containing the viral double stranded DNA (dsDNA) genome,
a tegument layer, consisting of numerous proteins of both viral and host origin surrounding the
nucleocapsid, and an envelope comprising a host-derived lipid bilayer inserted with viral glycoproteins
facing outwards (Figure 1A,B) [6–8]. Upon entry of a VZV virion into the host cell, tegument proteins
are released into the newly infected cell, altering the host environment, thereby inhibiting antiviral
responses and influencing the fate of the virus program, i.e., a lytic or latent infection (reviewed in
ref. [9]). The VZV dsDNA genome is about 125 kilo base pairs (kbp) in size and has a G + C content of
46%. It is composed of two unique segments, termed unique long (UL) and unique short (US), that are
flanked by inverted terminal repeat (TR) and internal repeat (IR) structures with high G + C contents
(68% for the TRL/IRL and 59% for the IRS/TRS) (Figure 1C) [10–19]. The very short (~88 bp) TRL and
IRL sequences flank the UL region, while the long (7319 bp) IRS and TRS sequences flank the US region.
The composite structure generally allows for two isomeric configurations [17] that differ only in terms
of whether the US region is inverted. While up to 5% of virions are reported to contain structural
isoforms with an inverted UL region [20], their relative scarcity is attributed to a unique DNA sequence
at the extreme 5′ end of the UL region that is required for viral DNA cleavage during packaging [21]
i.e., these virions may not contain functional genomes. Five regions of the genome contain tandem
direct reiterations (R1, R2, R3, R4, and R5) of short repeat sequences, one of which (R4) is located in
the IRS/TRS. All except R5 are G + C rich, and all are subject to length and structural polymorphisms
that vary both within and between strains [22–26]. Three of these reiterative regions (R1, R2, and R3)
are located within the coding portion of VZV genes (open reading frame (ORF) 11, ORF14, and ORF20,
respectively) and may therefore exert an effect on protein function. Two copies of R4 are present in the
IR and TR, neighboring the origin of replication (OriS), while R5 is located between ORF60 and ORF61.
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Figure 1. Structure of varicella-zoster virus (VZV) particles and genome. (A) Electron microscopy
image of VZV (obtained from Centers for Disease Control and Prevention (CDC)/Dr Erskine Palmer;
B.G. Partin. CDC Public Health Image Library). (B) Schematic representation of the VZV virion.
(C) Schematic representation of the VZV genome structure and G + C content. (D) The VZV
transcriptome profile during lytic infection of ARPE-19 cells (outer track) and latent infection of human
TG (trigeminal ganglia; inner track). Note that the low frequency of VZV-infected neurons in human
TG necessitates the use of targeted enrichment of VZV transcripts to detect VZV latency-associated
transcript (VLT) expression [27]. Circos plot of the VZV genome (UL, TR/IR, and US are shown as
purple, white, and grey bands, respectively; sense and antisense open reading frames (ORFs) are
indicated as red and blue blocks, respectively, with ORF numbers indicated where possible). Data
represent strand-specific VZV-enriched mRNA-sequencing with peaks facing outwards from the center
(black) indicating reads mapping to the sense strand, while peaks facing inward (grey) originate from
the antisense strand. The y-axis is scaled to the maximum read depth per library in all cases. dsDNA,
double-stranded DNA; UL, unique long; US, unique short; TR, terminal repeat; IR, internal repeat;
R, reiterative region; Ori, origin of replication.
2.2. Coding Potential of the VZV Genome
The VZV genome was originally reported to encode 65 unique viral genes, three of which are
located in the duplicated IRS/TRS region [19]. Four additional VZV genes have since been identified
including ORF0 [28], ORF9A [29], ORF33.5 [30], and the newly discovered VZV latency-associated
transcript (VLT) [27] (Figure 1D). An underappreciated feature of VZV is that transcription of several
genes, including ORF0, ORF42/45, ORF50, and VLT, require the host-splicing machinery to remove
introns from pre-mRNA and have also shown evidence of alternative splicing, resulting in the synthesis
of alternative proteins [19,27,31–33]. It thus seems likely that the full transcriptional potential of VZV
has yet to be revealed, and we predict that the latest technological advances (e.g., full length sequencing
of native RNA [34]) will yield further novel discoveries. It is also worth noting that the encoding of
additional RNA types, including microRNAs and small non-coding RNAs, is still an area of active study
with contrasting results [27,35,36]. How these studies might have an impact on our understanding of
viral latency remains to be seen.
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2.3. VZV Gene Expression during Productive Infection
Based on limited experimental data [37,38], and mostly by analogy to other alphaherpesviruses, VZV
genes have been loosely designated as immediate-early (IE) genes, early (E) genes, and late (L) genes,
with each ordered wave of expression thought to be dependent on the protein products of previous
classes. Proteins encoded by IE genes act as transcriptional regulators, while those produced by E genes
are mainly involved in DNA replication, and L genes encode structural proteins that are crucial for
virion formation and egress. VZV encodes at least five transcriptional regulatory proteins specified by
four putative IE genes, ORF4, ORF61, ORF62 and ORF63, and one L gene, ORF10. All except the ORF61
protein, IE61, are part of the VZV virion [39,40]. Our understanding of the transcriptional regulation
of VZV genes remains incomplete, in part due to the high cell-associated nature of VZV that precludes
synchronized infections using cell-free viruses. The dominant transcriptional regulator and possibly
only true immediate-early protein encoded by Varicellovirus is homologous to VZV IE62 [39,41–48].
Consistent with this idea, the VZV IE62 major viral transactivator protein can activate all three kinetic
classes of VZV genes in the absence of other viral proteins, including all IE genes, ORF4, ORF61, ORF62,
and ORF63, while IE4, IE61 and IE63 either do not or minimally stimulate the ORF61 promoter ([49–51],
reviewed in ref. [52]). Host transcription factors, either by themselves or through interactions with viral
transcriptional regulatory proteins, also contribute to viral gene expression (reviewed in ref. [52]). VZV
virion proteins delivered into newly infected cells upon entry are not absolutely required to initiate VZV
gene expression, as evidenced by the resulting VZV replication upon transfection of cells with viral
DNA (reviewed in ref. [53]). Notably, near identical VZV transcriptomes are detected during productive
infection of diverse cell types, including neurons [27,54–57], suggesting a prominent role for either
commonly expressed cellular transcription factors or viral proteins in coordinating VZV gene expression.
2.4. Stability of the VZV Genome
Recent advances in the fields of genomics and computational biology have led to an explosion
in high-throughput VZV genome sequencing studies [25,58–63], with multiple studies focused on
exploring the evolution of VZV [60,64,65]. Perhaps the most pertinent observations made by these
studies are that (i) the VZV genome is very stable with over 98% sequence conservation between the
most distant strain sequences to date, and (ii) the evolutionary history of VZV, like other herpesviruses,
is shaped by extensive recombination [60], the latter requiring that two or more different viral genomes
occupy the same cell nucleus during viral DNA replication. The live-attenuated nature of the VZV
vaccine has enabled comparative analyses of vaccine-induced varicella and HZ isolates, showing that
the VZV genome remains highly stable during latency [59,62].
3. Location of Latent VZV
3.1. Sites of VZV Latency
During primary infection, VZV infects and establishes lifelong latency in sensory neurons located
in the dorsal root ganglia (DRG) and trigeminal ganglia (TG). While VZV DNA has been detected
in various other sensory (geniculate, vestibular, and spiral ganglia) [5,66–68] and autonomic ganglia
(nodose, enteric, and thoracic sympathetic ganglia) [69–71], it remains unclear as to whether the virus
can establish latency and reactivate from all of these sites, i.e., infection of these sites may lead to the
persistence of only VZV genomes that are not capable of reactivating. The only confirmed sites at which
VZV can establish latency and reactivate are the DRG and TG, where the latent viral DNA is maintained
as a circular episome in ~2–5% of sensory neurons at a median of 5–7 genome copies per neuron [72–75].
Additionally, VZV DNA and a restricted number of viral transcripts have been detected in intestinal
biopsies of naturally infected and vaccinated individuals [69,76–78]. Although in situ detection of VZV
DNA or RNA in human enteric neurons is lacking, clinical evidence suggests that VZV reactivation from
the enteric nervous system (ENS) could be associated with gastrointestinal dysfunction [79–81], possibly
resulting from reactivation-induced damage to ENS neurons or virus replication in the gut wall.
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3.2. Entry of VZV into the Peripheral Nervous System
Two non-mutually exclusive routes by which VZV may infect sensory ganglion neurons have
been proposed (Figure 2A). First, VZV could enter nerve endings innervating the dermis at sites of
cutaneous lesions and gain access to ganglia by retrograde axonal transport. This route is supported by
the detection of viral antigens in Schwann cells and peripheral nerve axons in the dermis of varicella
patients [82], and observations that HZ occurs at the site of varicella vaccine inoculation [83] or the
sites most affected by varicella [4]. More recently, VZV infection of axons and retrograde axonal
transport to neuronal cell bodies was formally demonstrated in cell culture [84,85], possibly involving
fusion between VZV-infected non-neuronal cells and neuronal axons [86]. Notably, nerve endings
are located in close proximity to the cutaneous vasculature at the dermal–epidermal junction and
in hair follicles [87], supporting a model in which VZV may concurrently infect epidermal or hair
follicle keratinocytes and neurons via local cell-to-cell spread. Second, VZV-infected lymphocytes,
most likely T-cells, could disseminate the virus to ganglia during varicella-associated viremia. This is
supported by detection of VZV DNA in ganglia obtained at autopsy from patients in the prodromal
stage of varicella [7]. Moreover, localized injection of live-attenuated VZV vaccine virus results in
the establishment of viral latency in bilateral DRGs and enteric ganglia [76]. VZV infects T-cells,
prolongs their survival via STAT3 phosphorylation and induction of survivin [88], and modulates
their phenotype to induce an activated skin-tropic memory T-cell [89–91]. While the prerequisites
for T-cell entry into ganglia are unknown, intravenously injected VZV-infected tonsillar T-cells have
been shown to transfer the virus to human foetal DRG xenografts implanted under the kidney capsule
in severe combined immunodeficiency (SCID) mice [92]. Moreover, T-cells infected with the simian
varicella virus (SVV), the closest relative to VZV and natural cause of varicella and HZ in non-human
primates, has been detected in the ganglia of non-human primates during primary infection [93].
Thus, the definitive route(s) by which VZV infects ganglionic neurons, with or without cutaneous
innervation, needs to be investigated in future studies.
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Figure 2. Schematic representation of the establishment of, and reactivation from, VZV latency in
sensory neurons. (A) VZV gains access to sensory ganglion neurons via the infection of nerve endings
in skin and retrograde axonal transport to the neuronal cell body (1) or direct infection of cell bodies
via VZV-infected T-cells (2), followed by the release of the viral genome into the nucleus (3). (B) VZV
reactivation results in virus replication and spread in the cell body (1), followed by transaxonal spread
to the skin to cause HZ (2), possibly involving concordant virus spread to the spinal cord (3). (C) VZV
latently infected sensory neurons contain viral episomal DNA in their nuclei and express VLT and/or
ORF63 RNA, as shown by RNA in situ hybridization on human TG (red signal). Magnification: 400×
with 2.5× digital zoom.
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4. Transcriptional Repression of Latent VZV Genomes
In the absence of robust animal models, VZV latency studies have been dominated by the use of
naturally VZV-infected cadaveric human ganglia, either snap-frozen at autopsy [94] or explanted into
short term cultures (reviewed in ref. [95]), although the latter is not reported to result in the production
of infectious virions [96]. More recently, the use of in vitro hESC-derived neurons has provided a
more accessible approach to latency studies [56,97], principally due to the ability to examine both the
establishment of, and reactivation from, latency in sequential fashion over longer periods using mutant
viruses and assays that are simply not compatible with wild type, VZV-infected, post-mortem ganglia.
4.1. VZV Transcription in Human Ganglia
The difficulty of obtaining and working with post-mortem human ganglia has resulted in
discrepant numbers and identities of viral transcripts, and in some cases, the corresponding proteins
have been detected [98–102]. The latter has been confounded by the use of ascites-derived murine
and rabbit antibodies that also contain endogenous antibodies that react with human blood type A
antigens expressed by sensory neurons [103,104]. Consequently, VZV protein expression in human
ganglia appears to be absent or extremely rare and is most likely associated with de-repression of the
latent viral genome or in the early stages of reactivation [98,100]. The role of cellular dysregulation
following death is undoubtedly a major influence [105], reflected by the post-mortem interval (PMI)
which is a major factor in determining the number and identity of viral transcripts present [106].
Most recently, unbiased virus nucleotide-enriched ultra-deep RNA-sequencing confirmed that viral
transcription in short-PMI (<9 h post mortem) human ganglia is highly restricted and limited to VLT,
frequently accompanied by co-expression of ORF63 RNA, albeit at lower quantities than VLT [27,73–75]
(Figure 2C). Interestingly, fewer TG neurons express VLT (on average, 0.49%) and ORF63 (0.36%) by
in situ hybridization than the reported 2–5% of neurons harboring latent VZV DNA [27], suggesting
that not all VZV genomes present in TG neurons are transcriptionally active. Although both VLT
and ORF63 RNA retain the potential to be translated during latency, these viral proteins could not
be detected in latently infected human ganglia by immunohistochemistry [27]. However, given the
very low abundance of VLT and ORF63 RNAs, alternative approaches with higher sensitivity, such as
screening for the loading of VLT and ORF63 RNA onto polysomes combined with targeted enrichment
for viral RNAs could provide conclusive data. Thus, VZV latency in naturally infected human ganglia
is characterized by the exclusive expression of VLT and often, ORF63.
4.2. Comparison of VZV Latency In Vivo and In Vitro
Although naturally VZV-infected, short-PMI, human cadaveric ganglia most closely resemble
in vivo VZV latency, ganglia from these individuals are likely to have been latently infected for many
decades. In contrast, when using in vitro hESC-derived neuronal models, latency is usually profiled
within 14 days. Although transcriptome-wide profiling by RNA-sequencing of in vitro “latent” VZV
infections has revealed a marked reduction in viral gene expression, all viral genes are expressed in the
absence of detectable levels of viral proteins [56,97]. While limited enrichment for the classical VZV
latency-associated ORF63 RNA has been observed, it is not known whether these systems express
detectable VLT and if so, whether the latent VLT isoform is transcribed [27,56,97]. This has led to
the introduction of new terminology, such as non-productive or quiescent infections, and questions
over the relative merits of in vitro models. As a counterpoint, these models have proven to be highly
informative of early events during the VZV infection of neurons and the establishment of latency.
Moreover, in vitro models remain the only system in which the establishment of latency and subsequent
reactivation can be studied, with these studies, as a whole, benefitting increasingly from continual
improvements in culture longevity and axonal infection protocols.
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4.3. Epigenetic Silencing of the Latent VZV Genome
The molecular mechanisms by which VZV latency is established are largely unknown and
much of what is assumed is actually informed by studies of the related herpes simplex virus type 1
(HSV-1). Here, the key concept is that during the traversal of neuronal axons, the genome-containing
nucleocapsid is delivered to the nucleus in the absence of functional tegument proteins for IE gene
transcription (i.e., VZV ORF10 protein—the homolog of HSV-1 virion protein 16 [VP16]), and this
allows loading and maintenance of repressive chromatin upon the viral episome which inhibits viral
transcription ([107] and reviewed in ref. [108]). Whether this is a rapid or slow process is not known,
although data from VZV in vitro models may provide support for the latter, i.e., viral transcription in
newly infected neurons is gradually suppressed over time, eventually leading to the transcriptional
profile that we correlate with latency in human ganglia (i.e., the expression of VLT and frequently,
ORF63 RNA). Either way, the remarkable switch between lytic and latent transcriptional states is best
explained by the assembly of repressive chromatins upon the viral episome. Indeed, studies using
late PMI (>9 h post mortem) VZV-latently infected human ganglia have demonstrated euchromatic
(H3K9ac) chromatin modifications on promoters of latency-associated ORF63 and ORF62, the latter
of which is frequently expressed in late PMI deregulated ganglia [109]. In contrast, promoters of
viral genes, ORF14 and ORF36, which are not expressed during latency, nor detected in late-PMI
ganglia, have not been associated with H3K9ac [109]. The increase in viral transcription with increasing
post-mortem intervals suggests that these studies need to be extended to shorter PMI and genome-wide
analyses. Indeed, one might speculate that all but VLT and ORF63 loci would be bound by repressive
chromatin, and it will be important to determine whether the VLT locus remains active due to the
presence of predicted sequence motifs for flanking chromatin insulators such as CCCTC-binding factor
(CTCF), as has been observed for HSV-1 [110].
5. The Varicella Zoster Virus Latency-Associated Transcripts: VLT and ORF63
While all alphaherpesviruses express latency-associated transcripts (LATs), their size, coding
potential, functions, and mechanisms of action may vary.
The identification of VLT represents a major advance in studies of VZV latency. VLT is encoded
antisense to the ORF61, and it is remarkable to note that all known alphaherpesvirus latency-associated
transcripts (LATs) originate from genomic regions encoding infected cell polypeptide 0 (ICP0) homologs
(Figure 3). This is indicative of significant evolutionary conservation, although the encoding of LATs and
ICP0 homologs antisense to each other makes it harder to assess their individual contributions toward the
maintenance of this locus. Notably, VZV appears to be the only alphaherpesvirus that has been analysed
in detail to date that consistently expresses an additional latency transcript, ORF63, in human TGs.
5.1. Comparison of VLT and LATs of Related Alphaherpesviruses
VLT is a polyadenylated RNA comprising at least five distinct exons and is encoded antisense to
VZV ORF61, a homolog of the HSV RL2 gene (encoding ICP0). During latency, a single VLT isoform
is expressed in the neurons of virtually all analysed VZV-infected human TGs [27], although it is
not known whether VLT is expressed in all VZV-infected neurons. VLT appears to be structurally
complex compared to the LATs of HSV-1, pseudorabies virus (PRV) and bovine herpesvirus 1 (BHV-1),
which are composed of only two exons and a single intron (Figure 3). The possible exception is the
closest relative of VZV, the non-human primate SVV, which expresses a transcript mapping to the
same region as VLT during latency [111,112], although more detailed studies are needed to determine
the exact location and structure of the SVV VLT homolog. Unlike the stable LAT introns of HSV-1 that
accumulate to high abundancies in latently infected human TG [27,113], VLT appears to be expressed
at relatively few copies per neuron [27]. Furthermore, while the LATs of HSV-1, PRV, and BHV1 encode
viral miRNAs [114–116], there is no evidence for the expression of VZV miRNAs encoded within
VLT—or anywhere else in the VZV genomes—in latently-infected human ganglia [27].
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Figure 3. Comparison of latency-associated transcripts among alphaherpesviruses. All alphaherpesvirus
latency-associated transcripts (LATs) are located antisense to the infected cell polypeptide 0 (ICP0)
locus, encoding a conserved major immediate-early transactivator (ICP0 or homologs). (A) The VZV
latency-associated transcript (VLT) is a 496-nucleotide, multi-exon mRNA that is partially antisense
to the ORF61 coding region via exons 3 and 4. (B) Transcripts mapping antisense to simian varicella
virus ORF61 are expressed during latency (dotted arrow), but their identity has not yet been defined.
(C) Bovine herpesvirus 1 encodes a 2.2 kb latency-related (LR) RNA and encodes two miRNAs in exon
1 (D) The pseudorabies virus large latency transcript (LLT) is the largest characterized alphaherpesvirus
latency transcript and encodes eleven distinct miRNAs within the spliced intron. (E) The 8.2 kb herpes
simplex virus type 1 (HSV-1) LAT undergoes splicing which yields two highly stable intron lariats,
approximately 1.5 and 2.0 kb in size (shown as circles). Note that latency transcripts are shown as
grey arrows, immediate early viral transactivators as dark red arrows, and encoded miRNAs as short
vertical lines. Scaling across all schematics is equal.
Although VLT is the predominant transcript expressed during latency, its expression is not
restricted to the latent phase. During VZV lytic infections of epithelial cell or melanoma cell cultures,
multiple alternatively spliced VLT isoforms were identified [27]. Termed VLTly, these lytic isoforms
are transcriptionally more complex than the “core” latent VLT isoform detected during latency. Exon
skipping, intron retention, and additional upstream exons are all features of VLTly, with most variation
apparently occurring between “core” exons 3 and 4. Notably, the core latent VLT isoform has never
been observed in lytic infections which may suggest that the core isoform is driven by a cell type
(i.e., neuron) specific promoter. During productive infections, VLTly is transcribed with true-late
kinetics, is defined as being absolutely dependent on viral replication, and is translated into proteins
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(pVLT) in cell cultures and zoster skin lesions [27]. Although the expression and function of LATs
during lytic alphaherpesvirus infection is incompletely understood, the observed features of VLT are
consistent with the general pattern of LATs. During lytic infection, LATs appear to be expressed with
late kinetics [27,117]. Alternative LAT isoforms are produced using different transcription start sites or
alternative splicing [27,118,119], and some LATs encode proteins [27,120]. Given that hESC neuronal
models support both lytic and quiescent VZV infections [56,97], these could be particularly useful for
investigating the regulation of lytic and latent isoforms of VLT in the same cell type.
5.2. Function(s) of VLT
The functional characterization of VLT during lytic and latent stages is now a priority. Early
investigations using transfection assays showed that VLT selectively represses ORF61 transcription
when co-expressed with multiple VZV coding IE genes (ORF61, ORF62 and ORF63) in ARPE-19
epithelial cell cultures, resulting in diminished expression of the ORF61 protein, IE61 [27]. This effect
is not pVLT-specific as mutations of the initiating ATG start codon (to ATA) showed a similar
effect—suggesting that it is mediated by the RNA itself. While the specific functions and requirements
of VLT and VLTly isoforms during lytic and latent infections remain unknown, these data allow us
to speculate that VLT may function to maintain latency by repressing the transcription of ORF61, a
promiscuous transcriptional regulator, during lytic infections. However, it will be pivotal to confirm
these observations in other experimental systems, especially since not all functions attributed to LATs
of related herpesviruses in vitro can subsequently be confirmed in vivo [121,122].
5.3. Function(s) of ORF63
VZV expresses two latency-associated transcripts, VLT and ORF63 RNA, the expression of which
correlates significantly in human TG, independent of the latent viral DNA load [27], suggesting that
expression of both transcripts is linked. It is unclear whether VLT and ORF63 RNA are produced
by the same or by distinct populations of neurons, and how this may influence the ability of the
virus to reactivate. ORF63 is essential for VZV replication [123] and its encoded protein, IE63,
functions not only as a transcriptional regulator activating E genes [124] but also modifies neuronal
susceptibility to apoptosis and functions as a immunoevasin that blocks type I interferon (IFN)
signaling [125–127]. As such, we speculate that ORF63, once translated (IE63), could be crucial for the
initiation of reactivation, supported by the correlation between ORF63 RNA abundance and PMI [106].
The observation that IE61 is required for nuclear entry of IE63 in guinea pig enteric neurons, yet to be
determined in human neurons [128], suggests that VLT-mediated repression of ORF61 transcription
and translation may also function to retain IE63 in the cytoplasm and prevent the transactivation of
lytic viral promoters (Figure 4A).
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Figure 4. Schematic representation of the regulation of VZV latency and reactivation. The activation of
neuronal signaling pathways in response to stimuli at the periphery (2) and possibly, within the spinal
cord (3) may induce VZV reactivation. At the same time, adaptive T-cell-mediated immune responses
in skin (1) and ganglia (4), and the local ganglionic innate immunity provided by neuron-interacting
satellite glial cells (SGC) are believed to prevent symptomatic VZV reactivation.
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6. VZV Reactivation: Restarting Lytic Gene Expression
Symptomatic VZV reactivation, which leads to HZ and/or associated pathologies, typically occurs
just once or twice in an infected individual’s lifetime and likely requires two events—stimulus of a
latently-infected neuron and the overriding of existing immune protection mechanisms. In contrast,
asymptomatic reactivation is thought to occur more frequently [2,129]. Possibly, the phase of
intra-ganglionic virus replication that is presumed to occur upon VZV reactivation [130,131] (Figure 2B)
before the virus descends down sensory axons to the skin provides the host immune system more
time to control most reactivation events before becoming symptomatic. The environmental factors
and molecular mechanisms that underpin VZV reactivation in humans remain poorly understood.
Clinical observations of HZ after trauma [132] or neurosurgery [133,134] suggest that signalling events
from the periphery may induce VZV reactivation in the soma of sensory neurons. Two main signalling
pathways have been implicated in VZV reactivation: the phosphatidylinositol-3 kinase (PI3K)-Akt
pathway and the mitogen-activated protein kinase (MAPK) pathway. The nerve growth factor (NGF)
receptor, TrkA, is expressed by a subpopulation of sensory neurons and signals via the PI3K-Akt and
MAPK pathways [135], and depletion of NGF from VZV-latently infected neurons can lead to the
reactivation of VZV in some in vitro latency systems [56,97]. The role of NGF signalling in contributing
to the maintenance of VZV latency has been confirmed in VZV-latently infected human TG removed
within 24 h after death [136]. Intriguingly, the effect of chemical PI3K blockade on VZV reactivation
depends on the experimental conditions, as PI3K inhibition did not reactivate VZV in ex vivo cultures
of naturally infected human TG neurons [136] and variable effects have been obtained in hESC-derived
neurons [56,97]. NGF depletion results in the phosphorylation and activation of the MAPK family
member, c-Jun N-terminal kinase (JNK) and is critical for efficient VZV replication in hESC neurons.
Selective JNK inhibition limits VZV reactivation in vitro, suggesting JNK signalling plays important
role for VZV reactivation in neurons [137].
To reactivate from latency, the latent viral episome needs to be de-repressed, and viral gene
expression has to occur as a downstream event of the PI3K-Akt and/or JNK pathways. The mechanisms
underlying the reversal of repressive chromatin on the VZV genome and the viral gene expression
machinery required for VZV reactivation are poorly understood. Unlike HSV-1, the inhibition of
histone deacetylases resulted in failed production of the infectious progeny virus [56], but led to
viral DNA replication and expression of late genes in vitro [97]. It may be that additional chromatin
modifications, like the methylation of histone H3 lysine 4 (H3K4) or demethylation of H3K9, need
to take place before VZV reactivation can occur [138]. Alternatively, JNK signalling may induce a
methyl/phospho switch on promoters of VZV lytic genes that facilitates their expression and virus
reactivation as observed during HSV-1 latency and reactivation [139]. Clearly, additional environmental
factors and neuronal signalling pathways are involved, and the overall outcome of VZV infection will
be determined by the combined integration of all these pathways.
7. Intrinsic, Innate, and Adaptive Immunity to VZV Infection in Ganglia
The intrinsic properties of neurons and the innate and adaptive immune responses mounted
by ganglion-resident or infiltrating cells that contribute to the control of VZV replication in ganglia
are unknown. VZV infection of human foetal DRG xenografts in SCID mice produces transient
virus replication and spread, followed by persistently lower levels of viral DNA and limited viral
transcription after 4–8 weeks [92], suggesting that adaptive immune responses are not essential for
the control of VZV replication in this model system. Intrinsic differences in neuronal subpopulations
affect the outcome of VZV infection, as virus replication is blocked in neurons expressing the
mechanoreceptive marker RT97, but not in neurons expressing the nociceptive marker peripherin [140].
However, it is not clear which neuron subtype(s) harbor latent VZV in naturally infected humans and
whether all neurons are equally capable of supporting VZV reactivation.
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7.1. Satellite Glial Cells and Innate Immunity
Although sensory neurons produce little type I IFN α/β, neurons are sensitive to IFN-α/β
signalling, as the exposure to IFN-α/β at nerve endings prevents retrograde axonal transport of
alphaherpesvirus virions [141]. Notably, various cytokines/chemokines are produced in VZV-infected
foetal DRG, including IFN-α, interleukin 1 alpha (IL-1α), IL-6, CXCL10, and transforming growth
factor beta [140]. While the cellular source of these cytokines is unknown, satellite glial cells (SGC) are
prime candidates. SGC are a specialized ganglionic cell type that shares phenotypic and functional
features with professional antigen presenting cells like macrophages and dendritic cells [142,143]. SGC
completely enwrap the neuronal cell body and provide physical and nutritional support to the neuron,
but also function as tissue-resident innate immune cells that express pattern recognition receptors
(e.g., Toll-like receptors), phagocytose, produce inflammatory mediators and potentially regulate local
T-cell responses [142–144]. Moreover, SGC surrounding HSV-1 infected neurons produce IL-6 and
tumour necrosis factor α [145], and we have shown that SGC are activated in response to primary
SVV infection in monkeys [146]. However, more detailed studies on the role of SGC in response to
ganglionic VZV infected are warranted.
7.2. T-Cell Immunity
VZV reactivation, clinically presenting as HZ, is associated with the waning of systemic
VZV-specific T-cell immunity, but not humoral immunity, suggesting a critical role of VZV-specific
T-cell memory in preventing virus reactivation [147,148]. However, a large fraction of pathogen-specific
memory T-cells are retained in organs, referred to as tissue-resident memory T-cells (TRM), and provide
swift protective immunity upon pathogen re-exposure [149,150]. In analogy to HSV-1 mouse
models [151–154] and human TG [155], VZV-specific TRM are expected to home to sites of latency
and reactivation in ganglia and skin. Indeed, recent studies showed that VZV-specific TRM cells
persist in the healthy skin of latently VZV-infected adults decades after primary infection [156].
Profound T-cell responses detected in ganglia of HZ patients hint at the presence of VZV-specific TRM
in ganglia [157,158]. While VZV-specific T-cells in latently infected human TG have not previously
been detected, this study analysed only a restricted panel of VZV proteins (IE4, ORF29 protein, IE62,
and IE63) [159]. More detailed studies are needed to determine the presence, specificity, and function
of VZV-specific TRM in latently VZV-infected human ganglia in regard to their contribution to VZV
latency and reactivation control. This will provide more insight into the inverse relationship between
VZV-specific T-cell immunity and the risk of HZ development.
8. Future Perspectives
VZV has evolved with the ability to establish lifelong latent infection in neurons, enabling the
virus to reactivate later in life and cause recrudescent disease accompanied by VZV spread to naïve
individuals. Throughout the decades of latency, the virus must ensure survival of the infected neuron,
avoid irreversible silencing of the viral episome, and prevent elimination by host immune responses.
Although the mechanisms that coordinate the interplay between the virus and the host remain largely
unknown, the many recent exciting advances in the field provide us with the questions to be addressed
and tools (ex vivo and in vitro latency models) that can be used to answer them. Thirty-five years on
from the discovery of latent VZV residing in sensory ganglia [5], the identification of VLT and the latent
VZV transcriptome in naturally-infected, short-PMI TG has provided us with an new perspective on
VZV latency [27]. With this advancement, we also propose to enhance the definition of VZV latency
as requiring (i) the presence of the viral genome as an episome in the nucleus of host cells without
production of infectious progeny, (ii) the capacity of latent VZV to reactivate and produce infectious
virus, and (iii) a distinct and restricted pattern of viral gene transcription, i.e., exclusive expression of
VLT and/or ORF63 RNA.
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It is now critical to determine the roles of (and potential interplay between) VLT and
ORF63 RNA in latently infected short-PMI human TG [106] and to analyse their functions in the
establishment of quiescence in human pluripotent stem cell (hPSC; hESC/hiPSC)-derived neuronal
models [56,97,160,161] or in the reactivation from latency using these same models and/or ex vivo
cultures of dissociated naturally VZV-infected human ganglia [136]. Human TG are composed of
diverse subtypes of neurons [162], and not all neuronal subpopulations may be equally susceptible to
VZV infection [140], as has been shown for HSV-1 [163,164]. Therefore, in situ analyses are required
to determine whether VLT and ORF63 RNA are co-expressed by the same or distinct neurons and
to define the subtypes of neurons harbouring the latent VZV genome. Recent developments in
the generation of recombinant VZV (reviewed in ref. [53]) will facilitate the functional analysis of
VLT/pVLT and ORF63 RNA/IE63 using hPSC-derived neuronal systems. Current evidence suggests
that both pVLT and IE63 are not expressed, or are expressed below detectable levels, in latently infected
ganglia [27,103,104]. While we have identified one possible function of the VLT RNA [27], no functions
are currently attributed to ORF63 RNA or pVLT.
Transcriptional regulation of VZV gene expression during lytic and latent infection has been poorly
defined. In analogy to HSV-1 [165], the reactivation of latent VZV is presumed to follow a regulated
cascade of gene expression, and more detailed analyses of lytic VZV transcriptional regulation are
warranted to provide insight into the requirements of VZV reactivation. Recent developments in
next-generation sequencing have facilitated the detection of low-abundant VZV genomes in latently
infected human TG [58,59] and will open up new avenues to unravel epigenetic modifications of latent
VZV genomes using chromatin immunoprecipitation sequencing (ChIP-seq) for histone modifications
or CTCF binding. Furthermore, in vitro quiescence models could be used to prospectively map
epigenetic chromatin modifications on the VZV genome during quiescent and reactivated stages
of infection. Of particular interest is also be the relative expression levels of VLT and ORF63 RNA,
and IE63 and IE61 during the initiation of virus reactivation.
The factors triggering and barriers restricting VZV reactivation are poorly understood and are of
great interest for future research. The infrequent clinical reactivation of latent VZV suggests that either
virus reactivation is rare or that most reactivation events are cleared before HZ can develop. Local
immune responses mediated by VZV-specific TRM in skin [156,166] or ganglion, or neuron-interacting
SGC [143,144] are likely to be pivotal factors controlling VZV reactivation, e.g., by secreting IFNs
to block early reactivation attempts [167]. The recently developed in vitro and ex vivo models to
study VZV reactivation [56,97,136,160,161] facilitate systematic analysis of the signalling pathways
modulating viral latency, and could be used to investigate the roles of non-neuronal cells and their
secreted antiviral factors in this process.
Post-mortem acquired human samples are extremely informative if handled carefully, especially
for investigating human-restricted pathogens like VZV, but they are also restrictive in that the resulting
datasets only represent a “snapshot” of latency. To overcome this, we hope that technological
advances in specific subtypic differentiation methodology for human sensory/sympathetic neurons or
organoid culture system from hPSC combined with single cell sequencing methodologies targeting
transcriptomes and epigenomes will provide novel ways to examine the dynamics of VZV latency and
provide new insight into the molecular mechanisms that control this.
Finally, the discovery of VLT and its potential role in governing VZV latency and/or reactivation
also opens up the tantalising possibility of re-engineering current VZV vaccines not to establish latency
or reactivate. While a significant amount of work is required to get from here to there, not least
determining whether VLT is truly required for latency and/or reactivation, pursuing this long term
goal gives new impetus to the VZV research field.
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